KFSHRC’s New US Patent Opens New Frontiers for Breast Cancer Treatment.

Riyadh: King Faisal Specialist Hospital and Research Centre (KFSHRC) announced a significant advancement in stem cell science, securing a US patent for an innovative method that holds promise for breast cancer treatment and regenerative medicine. In a press release issued by KFSHRC, it said that this innovative approach, developed by KFSHRC researchers Abdelilah Aboussekhra, Huda H. Al-Khalaf, and Hazem Ghebeh, involves transforming regular breast cells into multipotent stem cells using specialized culture methods. These stem cells have shown the ability to regenerate mammary tissue in animal models, presenting new possibilities for breast tissue reconstruction and advanced cancer therapies. According to Saudi Press Agency, the foundational research supporting this patent was published in the Molecular and Cellular Biology journal. This innovation offers a promising foundation for personalized breast cancer treatment, potentially providing enhanced reconstruction options for patients during the post-surgery period. Beyond its impact on regenerative medicine, the technique reflects KFSHRC's dedication to advancing life-saving therapies that address the needs of cancer patients worldwide. As a leader in advanced therapies, including localized CAR T-cell treatment for cancer, KFSHRC continues to set new standards in personalized care and transformative medical research to improve therapeutic outcomes for patients worldwide, said the release. KFSHRC has been ranked first in the Middle East and Africa and 20th globally in the list of the world's top 250 Academic Medical Centres for the second consecutive year, and has been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. Additionally, in the same year, it was ranked among the world's best 250 hospitals and included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.